

August 10, 2021

**Result posting of ARGX-117-2001 (2020-001546-19)**

Protocol title            A First-in-Human Study in Adult Subjects Hospitalized with COVID-19 Infection to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of ARGX-117

Protocol number        ARGX-117-2001

Dear Madam/Sir

The ARGX-117-2001 has been prematurely ended. The sponsor has decided to change strategy for the above mentioned compound in this disease area. It was decided to no longer continue the study ARGX-117- 2001/ARGOVID. No subjects have been enrolled in the study, as such no (partial) results are available.

Yours sincerely

DocuSigned by:  
*Adeline Boucher*

 Signer Name: Adeline Boucher  
Signing Reason: I approve this document  
Signing Time: 10-Aug-2021 | 2:41 PM CEST

A5EF217A7BE6458BA44164A812000A64

Adeline Boucher  
Head of Regulatory Affairs – Europe